1. Home
  2. ABEO vs RENE Comparison

ABEO vs RENE Comparison

Compare ABEO & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • RENE
  • Stock Information
  • Founded
  • ABEO N/A
  • RENE 2021
  • Country
  • ABEO United States
  • RENE United States
  • Employees
  • ABEO N/A
  • RENE N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • RENE Blank Checks
  • Sector
  • ABEO Health Care
  • RENE Finance
  • Exchange
  • ABEO Nasdaq
  • RENE Nasdaq
  • Market Cap
  • ABEO 277.6M
  • RENE 248.9M
  • IPO Year
  • ABEO 1980
  • RENE 2022
  • Fundamental
  • Price
  • ABEO $5.86
  • RENE $11.61
  • Analyst Decision
  • ABEO Strong Buy
  • RENE
  • Analyst Count
  • ABEO 3
  • RENE 0
  • Target Price
  • ABEO $18.00
  • RENE N/A
  • AVG Volume (30 Days)
  • ABEO 292.3K
  • RENE 230.1K
  • Earning Date
  • ABEO 11-14-2024
  • RENE 01-01-0001
  • Dividend Yield
  • ABEO N/A
  • RENE N/A
  • EPS Growth
  • ABEO N/A
  • RENE 42.92
  • EPS
  • ABEO N/A
  • RENE 0.43
  • Revenue
  • ABEO N/A
  • RENE N/A
  • Revenue This Year
  • ABEO N/A
  • RENE N/A
  • Revenue Next Year
  • ABEO $7,097.06
  • RENE N/A
  • P/E Ratio
  • ABEO N/A
  • RENE $26.90
  • Revenue Growth
  • ABEO 147.52
  • RENE N/A
  • 52 Week Low
  • ABEO $3.05
  • RENE $10.88
  • 52 Week High
  • ABEO $9.01
  • RENE $11.67
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 38.62
  • RENE 63.64
  • Support Level
  • ABEO $5.95
  • RENE $11.62
  • Resistance Level
  • ABEO $6.78
  • RENE $11.67
  • Average True Range (ATR)
  • ABEO 0.32
  • RENE 0.01
  • MACD
  • ABEO -0.07
  • RENE 0.00
  • Stochastic Oscillator
  • ABEO 7.07
  • RENE 64.71

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

Share on Social Networks: